|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CREB3L4 |
Gene summary for CREB3L4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CREB3L4 | Gene ID | 148327 |
| Gene name | cAMP responsive element binding protein 3 like 4 | |
| Gene Alias | AIBZIP | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8TEY5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 148327 | CREB3L4 | GSM4909286 | Human | Breast | IDC | 1.79e-02 | 2.61e-02 | 0.1081 |
| 148327 | CREB3L4 | GSM4909290 | Human | Breast | IDC | 1.55e-03 | 2.64e-01 | 0.2096 |
| 148327 | CREB3L4 | GSM4909293 | Human | Breast | IDC | 2.06e-29 | 6.57e-01 | 0.1581 |
| 148327 | CREB3L4 | GSM4909294 | Human | Breast | IDC | 2.29e-04 | 3.91e-01 | 0.2022 |
| 148327 | CREB3L4 | GSM4909297 | Human | Breast | IDC | 2.27e-02 | 1.03e-01 | 0.1517 |
| 148327 | CREB3L4 | GSM4909298 | Human | Breast | IDC | 8.66e-11 | 4.37e-01 | 0.1551 |
| 148327 | CREB3L4 | GSM4909302 | Human | Breast | IDC | 2.49e-02 | 2.34e-01 | 0.1545 |
| 148327 | CREB3L4 | GSM4909304 | Human | Breast | IDC | 3.92e-03 | 3.80e-01 | 0.1636 |
| 148327 | CREB3L4 | GSM4909306 | Human | Breast | IDC | 8.71e-09 | 4.46e-01 | 0.1564 |
| 148327 | CREB3L4 | GSM4909308 | Human | Breast | IDC | 2.74e-14 | 4.32e-01 | 0.158 |
| 148327 | CREB3L4 | GSM4909311 | Human | Breast | IDC | 1.24e-06 | 3.37e-02 | 0.1534 |
| 148327 | CREB3L4 | GSM4909312 | Human | Breast | IDC | 4.93e-06 | 4.85e-01 | 0.1552 |
| 148327 | CREB3L4 | GSM4909317 | Human | Breast | IDC | 2.74e-03 | 2.14e-01 | 0.1355 |
| 148327 | CREB3L4 | GSM4909319 | Human | Breast | IDC | 2.45e-13 | 1.31e-01 | 0.1563 |
| 148327 | CREB3L4 | GSM4909321 | Human | Breast | IDC | 5.90e-11 | 5.01e-01 | 0.1559 |
| 148327 | CREB3L4 | M1 | Human | Breast | IDC | 6.55e-07 | 3.17e-01 | 0.1577 |
| 148327 | CREB3L4 | M2 | Human | Breast | IDC | 1.94e-03 | 4.24e-01 | 0.21 |
| 148327 | CREB3L4 | DCIS2 | Human | Breast | DCIS | 2.17e-19 | -2.71e-02 | 0.0085 |
| 148327 | CREB3L4 | LZE22T | Human | Esophagus | ESCC | 5.54e-04 | 3.13e-01 | 0.068 |
| 148327 | CREB3L4 | LZE24T | Human | Esophagus | ESCC | 3.37e-10 | 2.28e-01 | 0.0596 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000698614 | Breast | IDC | response to unfolded protein | 30/1434 | 137/18723 | 1.24e-07 | 7.03e-06 | 30 |
| GO:003596614 | Breast | IDC | response to topologically incorrect protein | 32/1434 | 159/18723 | 3.71e-07 | 1.85e-05 | 32 |
| GO:003462013 | Breast | IDC | cellular response to unfolded protein | 23/1434 | 96/18723 | 6.73e-07 | 3.16e-05 | 23 |
| GO:003497614 | Breast | IDC | response to endoplasmic reticulum stress | 43/1434 | 256/18723 | 8.42e-07 | 3.82e-05 | 43 |
| GO:003596714 | Breast | IDC | cellular response to topologically incorrect protein | 24/1434 | 116/18723 | 6.27e-06 | 1.98e-04 | 24 |
| GO:003096812 | Breast | IDC | endoplasmic reticulum unfolded protein response | 17/1434 | 74/18723 | 3.37e-05 | 7.79e-04 | 17 |
| GO:000698622 | Breast | DCIS | response to unfolded protein | 30/1390 | 137/18723 | 6.24e-08 | 3.72e-06 | 30 |
| GO:003596622 | Breast | DCIS | response to topologically incorrect protein | 32/1390 | 159/18723 | 1.84e-07 | 9.15e-06 | 32 |
| GO:003497622 | Breast | DCIS | response to endoplasmic reticulum stress | 43/1390 | 256/18723 | 3.65e-07 | 1.71e-05 | 43 |
| GO:003462022 | Breast | DCIS | cellular response to unfolded protein | 23/1390 | 96/18723 | 3.90e-07 | 1.79e-05 | 23 |
| GO:003596722 | Breast | DCIS | cellular response to topologically incorrect protein | 24/1390 | 116/18723 | 3.68e-06 | 1.16e-04 | 24 |
| GO:003096821 | Breast | DCIS | endoplasmic reticulum unfolded protein response | 17/1390 | 74/18723 | 2.26e-05 | 5.32e-04 | 17 |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:0035966111 | Esophagus | ESCC | response to topologically incorrect protein | 125/8552 | 159/18723 | 1.44e-17 | 1.27e-15 | 125 |
| GO:0006986111 | Esophagus | ESCC | response to unfolded protein | 107/8552 | 137/18723 | 7.01e-15 | 3.87e-13 | 107 |
| GO:0035967111 | Esophagus | ESCC | cellular response to topologically incorrect protein | 90/8552 | 116/18723 | 1.94e-12 | 8.11e-11 | 90 |
| GO:0034620111 | Esophagus | ESCC | cellular response to unfolded protein | 74/8552 | 96/18723 | 3.10e-10 | 8.66e-09 | 74 |
| GO:003096818 | Esophagus | ESCC | endoplasmic reticulum unfolded protein response | 59/8552 | 74/18723 | 1.90e-09 | 4.36e-08 | 59 |
| GO:003497620 | Oral cavity | OSCC | response to endoplasmic reticulum stress | 178/7305 | 256/18723 | 2.59e-23 | 6.06e-21 | 178 |
| GO:003596620 | Oral cavity | OSCC | response to topologically incorrect protein | 117/7305 | 159/18723 | 6.93e-19 | 8.60e-17 | 117 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
| hsa0501623 | Breast | IDC | Huntington disease | 103/867 | 306/8465 | 5.14e-30 | 4.17e-28 | 3.12e-28 | 103 |
| hsa0471424 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
| hsa0491523 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
| hsa050312 | Breast | IDC | Amphetamine addiction | 18/867 | 69/8465 | 1.42e-04 | 1.36e-03 | 1.01e-03 | 18 |
| hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
| hsa0516324 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
| hsa0520322 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
| hsa0502033 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
| hsa0501633 | Breast | IDC | Huntington disease | 103/867 | 306/8465 | 5.14e-30 | 4.17e-28 | 3.12e-28 | 103 |
| hsa0471434 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
| hsa0491533 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
| hsa050313 | Breast | IDC | Amphetamine addiction | 18/867 | 69/8465 | 1.42e-04 | 1.36e-03 | 1.01e-03 | 18 |
| hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
| hsa0516334 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
| hsa0520332 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
| hsa0502043 | Breast | DCIS | Prion disease | 100/846 | 273/8465 | 1.44e-33 | 1.55e-31 | 1.14e-31 | 100 |
| hsa0501643 | Breast | DCIS | Huntington disease | 101/846 | 306/8465 | 1.54e-29 | 1.24e-27 | 9.13e-28 | 101 |
| hsa0471443 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
| hsa0491542 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| CREB3L4 | STM | Breast | ADJ | MIEN1,CD9,LRRC26, etc. | 2.79e-02 |  |
| CREB3L4 | GOB | Esophagus | Healthy | GOLM1,TFF3,CPE, etc. | 2.01e-01 |  |
| CREB3L4 | BN | Liver | Healthy | CLIC3,TTC39C-AS1,TMEM70, etc. | 4.34e-02 |  |
| CREB3L4 | FIB | Prostate | Tumor | TRGC1,KLK3,SPDEF, etc. | 5.19e-01 |  |
| CREB3L4 | CHIEF | Stomach | ADJ | PGC,C6orf58,FMOD, etc. | 4.01e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CREB3L4 | SNV | Missense_Mutation | novel | c.605N>G | p.Val202Gly | p.V202G | Q8TEY5 | protein_coding | deleterious(0) | possibly_damaging(0.767) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CREB3L4 | SNV | Missense_Mutation | c.806A>G | p.His269Arg | p.H269R | Q8TEY5 | protein_coding | tolerated(0.11) | benign(0.108) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CREB3L4 | SNV | Missense_Mutation | rs777111235 | c.458N>A | p.Cys153Tyr | p.C153Y | Q8TEY5 | protein_coding | tolerated(0.05) | benign(0.166) | TCGA-BH-A28Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CREB3L4 | SNV | Missense_Mutation | rs371608503 | c.584G>A | p.Arg195His | p.R195H | Q8TEY5 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CREB3L4 | SNV | Missense_Mutation | novel | c.793N>C | p.Glu265Gln | p.E265Q | Q8TEY5 | protein_coding | tolerated(0.35) | possibly_damaging(0.457) | TCGA-E2-A1LI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| CREB3L4 | insertion | Frame_Shift_Ins | novel | c.99_100insATGTTGACCAGGCTGGTCTTGAACT | p.Pro34MetfsTer16 | p.P34Mfs*16 | Q8TEY5 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| CREB3L4 | insertion | Frame_Shift_Ins | novel | c.361_362insGTTTCCCGGAGCTTTCTCCCAGCTTCCCGGCGATTCATATT | p.Ala121GlyfsTer27 | p.A121Gfs*27 | Q8TEY5 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| CREB3L4 | SNV | Missense_Mutation | rs762042967 | c.517N>A | p.Val173Ile | p.V173I | Q8TEY5 | protein_coding | tolerated(0.36) | benign(0) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CREB3L4 | SNV | Missense_Mutation | c.328N>T | p.Pro110Ser | p.P110S | Q8TEY5 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CREB3L4 | SNV | Missense_Mutation | novel | c.586N>G | p.Leu196Val | p.L196V | Q8TEY5 | protein_coding | deleterious(0) | possibly_damaging(0.727) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |